Valeant to buy worldwide rights to Dendreon's Provenge
January 29, 2015 at 21:29 PM EST
Jan 29 (Reuters) - Valeant Pharmaceuticals International Inc said it would buy the worldwide rights of Dendreon Corp's Provenge drug and certain other assets through a "stalking horse" deal for $296 million.
